Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2020 | ESMO Clinical Practice Guidelines: fertility preservation & management of post-treatment pregnancies

Matteo Lambertini • 9 Dec 2020
SABCS 2020
Breast Cancer

Matteo Lambertini, MD, PhD, IRCCS AOU San Martino (Ospedale Policlinico San Martino), Genova, Italy, discusses the recently published ESMO Clinical Practice Guidelines in fertility preservation and post-treatment pregnancies in post-pubertal cancer patients, these include sperm cryopreservation and oocyte/embryo cryopreservation, ovarian tissue cryopreservation and that post-treatment pregnancies in breast cancer survivors should not be discouraged. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Disclosures

Dr. Matteo reports advisory roles for Roche, Novartis, Lilly, AstraZeneca and speakers honoraria from Roche, Novartis, Lilly, Pfizer, Sandoz, Takeda.

More from Matteo Lambertini

ALTTO explanatory analysis: adjuvant AI or tamoxifen in pts with HR+/HER2+ early breast cancer
3:07
ALTTO explanatory analysis: adjuvant AI or tamoxifen in pts with HR+/HER2+ early breast cancer
Matteo Lambertini • 11 Dec 2025
PREFER: fertility & ovarian function preservation in premenopausal women with early breast cancer
3:11
PREFER: fertility & ovarian function preservation in premenopausal women with early breast cancer
Matteo Lambertini • 11 Dec 2025
Elucidating the causes of non-adherence to treatments in breast cancer
1:53
Elucidating the causes of non-adherence to treatments in breast cancer
Matteo Lambertini • 20 Oct 2025
How can clinicians enhance drug adherence in early-stage breast cancer?
2:32
How can clinicians enhance drug adherence in early-stage breast cancer?
Matteo Lambertini • 20 Oct 2025

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals